Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here’s what investors should know.
Viatris missed analysts’ revenue expectations by 0.7% last quarter, reporting revenues of $3.25 billion, down 11.2% year on year. It was a mixed quarter for the company, with a narrow beat of analysts’ full-year EPS guidance estimates but full-year revenue guidance slightly missing analysts’ expectations.
Is Viatris a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Viatris’s revenue to decline 9.5% year on year to $3.44 billion, a further deceleration from the 3.1% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.56 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Viatris has missed Wall Street’s revenue estimates six times over the last two years.
Looking at Viatris’s peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 3.2%, missing analysts’ expectations by 2.5%, and Supernus Pharmaceuticals reported a revenue decline of 1.7%, topping estimates by 7.4%.
Read our full analysis of Amneal’s results here and Supernus Pharmaceuticals’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Viatris is down 2.3% during the same time and is heading into earnings with an average analyst price target of $11.14 (compared to the current share price of $8.99).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.